AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission

This study is testing whether combining two drugs — azacitidine and venetoclax — as maintenance therapy (ongoing low-intensity treatment to prevent relapse) can keep AML in remission in younger adults who have achieved their first complete remission. **You may be eligible if...** - You are between 18 and 64 years old - You have been diagnosed with favorable-risk AML (a specific genetic subtype with a generally good prognosis) - You are in your first complete remission after standard induction and consolidation chemotherapy - You are not immediately going to have a bone marrow transplant **You may NOT be eligible if...** - You have relapsed or refractory AML - You have significant liver or kidney problems - You have an active uncontrolled infection - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.